The IRA May Accelerate Generic And Biosimilar Competition :

The IRA may alter the incentives drug firms have to pursue evergreening strategies, as having generic or biosimilar competition can exempt a drug from price negotiation.

Related Keywords

United States , American , Janssen Stelara , Medicaid Services , Journal Of The American Medical Association , Centers For Medicare , Drug Administration , Inflation Reduction , American Medical Association , Cms , Centers For Medicare And Medicaid Services , Generic , Biosimilar , Cms Guidance , Inflation Reduction Act ,